{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:18:57Z","timestamp":1786979937819,"version":"build-2736575974"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T00:00:00Z","timestamp":1712361600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T00:00:00Z","timestamp":1712361600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the National Clinical Key Specialty Construction Program, P. R. China (2023)."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s00277-024-05719-7","type":"journal-article","created":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T00:01:40Z","timestamp":1712361700000},"page":"2073-2087","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy and prognostic factors of allogeneic hematopoietic stem cell transplantation treatment for adolescent and adult Tlymphoblastic leukemia \/lymphoma: a large cohort multicenter study in China"],"prefix":"10.1007","volume":"103","author":[{"given":"Lan","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinjie","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jijun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dehui","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunji","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,6]]},"reference":[{"key":"5719_CR1","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/ejh.12722","volume":"96","author":"R Bassan","year":"2016","unstructured":"Bassan R, Maino E, Cortelazzo S (2016) Lymphoblastic lymphoma: an updated review on biology, diagnosis, and treatment. Eur J Haematol 96:447\u2013460. https:\/\/doi.org\/10.1111\/ejh.12722","journal-title":"Eur J Haematol"},{"issue":"Suppl 3","key":"5719_CR2","doi-asserted-by":"publisher","first-page":"S214","DOI":"10.3816\/CLM.2009.s.015","volume":"9","author":"D Hoelzer","year":"2009","unstructured":"Hoelzer D, G\u00f6kbuget N (2009) T-cell lymphoblastic lymphoma and T-cell acute lymphoblastic leukemia: a separate entity? Clin Lymphoma Myeloma 9(Suppl 3):S214\u2013221. https:\/\/doi.org\/10.3816\/CLM.2009.s.015","journal-title":"Clin Lymphoma Myeloma"},{"key":"5719_CR3","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/leu.2013.312","volume":"28","author":"P Jain","year":"2014","unstructured":"Jain P, Kantarjian H, Ravandi F et al (2014) The combination of hyper-CVAD plus nelarabine as frontline therapy in adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma: MD Anderson Cancer Center experience. Leukemia 28:973\u2013975. https:\/\/doi.org\/10.1038\/leu.2013.312","journal-title":"Leukemia"},{"key":"5719_CR4","first-page":"416","volume":"95","author":"A Reiter","year":"2000","unstructured":"Reiter A, Schrappe M, Ludwig WD et al (2000) Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report. Blood 95:416\u2013421","journal-title":"Blood"},{"key":"5719_CR5","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1182\/blood-2002-05-1483","volume":"101","author":"JE Levine","year":"2003","unstructured":"Levine JE, Harris RE, Loberiza FR et al (2003) A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma. Blood 101:2476\u20132482. https:\/\/doi.org\/10.1182\/blood-2002-05-1483","journal-title":"Blood"},{"key":"5719_CR6","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1093\/annonc\/mdl426","volume":"18","author":"KW Song","year":"2007","unstructured":"Song KW, Barnett MJ, Gascoyne RD et al (2007) Primary therapy for adults with T-cell lymphoblastic lymphoma with hematopoietic stem-cell transplantation results in favorable outcomes. Ann Oncol off J Eur Soc Med Oncol 18:535\u2013540. https:\/\/doi.org\/10.1093\/annonc\/mdl426","journal-title":"Ann Oncol off J Eur Soc Med Oncol"},{"key":"5719_CR7","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1200\/JCO.2015.61.5385","volume":"34","author":"S Lepretre","year":"2016","unstructured":"Lepretre S, Touzart A, Vermeulin T et al (2016) Pediatric-Like Acute lymphoblastic leukemia therapy in adults with lymphoblastic lymphoma: the GRAALL-LYSA LL03 Study. J Clin Oncol off J Am Soc Clin Oncol 34:572\u2013580. https:\/\/doi.org\/10.1200\/JCO.2015.61.5385","journal-title":"J Clin Oncol off J Am Soc Clin Oncol"},{"key":"5719_CR8","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1002\/ajh.22071","volume":"86","author":"VL Lazarevic","year":"2011","unstructured":"Lazarevic VL, Remberger M, H\u00e4gglund H et al (2011) Myeloablative allogeneic stem cell transplantation for lymphoblastic lymphoma in Sweden: a retrospective study. Am J Hematol 86:709\u2013710. https:\/\/doi.org\/10.1002\/ajh.22071","journal-title":"Am J Hematol"},{"key":"5719_CR9","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.3389\/fonc.2020.01423","volume":"10","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Qian J-J, Zhou Y-L et al (2020) Comparison of early T-Cell precursor and Non-ETP subtypes among 122 Chinese adults with Acute Lymphoblastic Leukemia. Front Oncol 10:1423. https:\/\/doi.org\/10.3389\/fonc.2020.01423","journal-title":"Front Oncol"},{"key":"5719_CR10","first-page":"1860","volume":"31","author":"PP Carbone","year":"1971","unstructured":"Carbone PP, Kaplan HS, Musshoff K et al (1971) Report of the Committee on Hodgkin\u2019s Disease staging classification. Cancer Res 31:1860\u20131861","journal-title":"Cancer Res"},{"key":"5719_CR11","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME et al (2007) Revised response criteria for malignant lymphoma. J Clin Oncol off J Am Soc Clin Oncol 25:579\u2013586. https:\/\/doi.org\/10.1200\/JCO.2006.09.2403","journal-title":"J Clin Oncol off J Am Soc Clin Oncol"},{"key":"5719_CR12","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","volume":"376","author":"H Kantarjian","year":"2017","unstructured":"Kantarjian H, Stein A, G\u00f6kbuget N et al (2017) Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. N Engl J Med 376:836\u2013847. https:\/\/doi.org\/10.1056\/NEJMoa1609783","journal-title":"N Engl J Med"},{"key":"5719_CR13","doi-asserted-by":"publisher","first-page":"3363","DOI":"10.1200\/JCO.2008.19.3367","volume":"27","author":"B Burkhardt","year":"2009","unstructured":"Burkhardt B, Reiter A, Landmann E et al (2009) Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from the berlin-frankfurt-muenster group. J Clin Oncol off J Am Soc Clin Oncol 27:3363\u20133369. https:\/\/doi.org\/10.1200\/JCO.2008.19.3367","journal-title":"J Clin Oncol off J Am Soc Clin Oncol"},{"key":"5719_CR14","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1002\/pbc.21941","volume":"52","author":"T Mitsui","year":"2009","unstructured":"Mitsui T, Mori T, Fujita N et al (2009) Retrospective analysis of relapsed or primary refractory childhood lymphoblastic lymphoma in Japan. Pediatr Blood Cancer 52:591\u2013595. https:\/\/doi.org\/10.1002\/pbc.21941","journal-title":"Pediatr Blood Cancer"},{"key":"5719_CR15","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s00277-006-0169-2","volume":"85","author":"SC Won","year":"2006","unstructured":"Won SC, Han JW, Kwon SY et al (2006) Autologous peripheral blood stem cell transplantation in children with Non-hodgkin\u2019s lymphoma: a report from the Korean society of pediatric hematology-oncology. Ann Hematol 85:787\u2013794. https:\/\/doi.org\/10.1007\/s00277-006-0169-2","journal-title":"Ann Hematol"},{"key":"5719_CR16","first-page":"1015","volume":"23","author":"JW Sweetenham","year":"2009","unstructured":"Sweetenham JW (2009) Treatment of lymphoblastic lymphoma in adults. Oncol Williston Park N 23:1015\u20131020","journal-title":"Oncol Williston Park N"},{"key":"5719_CR17","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.critrevonc.2010.12.003","volume":"79","author":"S Cortelazzo","year":"2011","unstructured":"Cortelazzo S, Ponzoni M, Ferreri AJM, Hoelzer D (2011) Lymphoblastic lymphoma. Crit Rev Oncol Hematol 79:330\u2013343. https:\/\/doi.org\/10.1016\/j.critrevonc.2010.12.003","journal-title":"Crit Rev Oncol Hematol"},{"key":"5719_CR18","doi-asserted-by":"publisher","first-page":"106627","DOI":"10.1016\/j.leukres.2021.106627","volume":"108","author":"S Yasuda","year":"2021","unstructured":"Yasuda S, Najima Y, Konishi T et al (2021) Outcome of allogeneic hematopoietic stem cell transplantation for T-cell lymphoblastic leukemia\/lymphoma: a single-center study. Leuk Res 108:106627. https:\/\/doi.org\/10.1016\/j.leukres.2021.106627","journal-title":"Leuk Res"},{"key":"5719_CR19","doi-asserted-by":"publisher","first-page":"1193237","DOI":"10.3389\/fonc.2023.1193237","volume":"13","author":"Z Li","year":"2023","unstructured":"Li Z, Zhang B, Fan X et al (2023) Selection of hematopoietic stem cell transplantation for T-cell lymphoblastic lymphoma. Front Oncol 13:1193237. https:\/\/doi.org\/10.3389\/fonc.2023.1193237","journal-title":"Front Oncol"},{"key":"5719_CR20","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1182\/blood-2015-08-661702","volume":"127","author":"N Jain","year":"2016","unstructured":"Jain N, Lamb AV, O\u2019Brien S et al (2016) Early T-cell precursor acute lymphoblastic leukemia\/lymphoma (ETP-ALL\/LBL) in adolescents and adults: a high-risk subtype. Blood 127:1863\u20131869. https:\/\/doi.org\/10.1182\/blood-2015-08-661702","journal-title":"Blood"},{"key":"5719_CR21","doi-asserted-by":"publisher","first-page":"846573","DOI":"10.3389\/fonc.2022.846573","volume":"12","author":"J Xiao","year":"2022","unstructured":"Xiao J, Cai Z, Wang H et al (2022) The clinical characteristics and prognosis of AYA and older adult ETP-ALL\/LBL: a real-world Multicenter Study in China. Front Oncol 12:846573. https:\/\/doi.org\/10.3389\/fonc.2022.846573","journal-title":"Front Oncol"},{"key":"5719_CR22","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1111\/bjh.12882","volume":"166","author":"K Patrick","year":"2014","unstructured":"Patrick K, Wade R, Goulden N et al (2014) Outcome for children and young people with early T-cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003. Br J Haematol 166:421\u2013424. https:\/\/doi.org\/10.1111\/bjh.12882","journal-title":"Br J Haematol"},{"key":"5719_CR23","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1111\/ejh.12238","volume":"92","author":"A Chopra","year":"2014","unstructured":"Chopra A, Bakhshi S, Pramanik SK et al (2014) Immunophenotypic analysis of T-acute lymphoblastic leukemia. A CD5-based ETP-ALL perspective of non-ETP T-ALL. Eur J Haematol 92:211\u2013218. https:\/\/doi.org\/10.1111\/ejh.12238","journal-title":"Eur J Haematol"},{"key":"5719_CR24","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1002\/ajh.26144","volume":"96","author":"K Morita","year":"2021","unstructured":"Morita K, Jain N, Kantarjian H et al (2021) Outcome of T-cell acute lymphoblastic leukemia\/lymphoma: focus on near-ETP phenotype and differential impact of nelarabine. Am J Hematol 96:589\u2013598. https:\/\/doi.org\/10.1002\/ajh.26144","journal-title":"Am J Hematol"},{"key":"5719_CR25","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/nature10725","volume":"481","author":"J Zhang","year":"2012","unstructured":"Zhang J, Ding L, Holmfeldt L et al (2012) The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 481:157\u2013163. https:\/\/doi.org\/10.1038\/nature10725","journal-title":"Nature"},{"key":"5719_CR26","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1038\/leu.2010.203","volume":"24","author":"C Kox","year":"2010","unstructured":"Kox C, Zimmermann M, Stanulla M et al (2010) The favorable effect of activating NOTCH1 receptor mutations on long-term outcome in T-ALL patients treated on the ALL-BFM 2000 protocol can be separated from FBXW7 loss of function. Leukemia 24:2005\u20132013. https:\/\/doi.org\/10.1038\/leu.2010.203","journal-title":"Leukemia"},{"key":"5719_CR27","doi-asserted-by":"publisher","first-page":"4352","DOI":"10.1200\/JCO.2009.22.0996","volume":"27","author":"MR Mansour","year":"2009","unstructured":"Mansour MR, Sulis ML, Duke V et al (2009) Prognostic implications of NOTCH1 and FBXW7 mutations in adults with T-cell acute lymphoblastic leukemia treated on the MRC UKALLXII\/ECOG E2993 protocol. J Clin Oncol off J Am Soc Clin Oncol 27:4352\u20134356. https:\/\/doi.org\/10.1200\/JCO.2009.22.0996","journal-title":"J Clin Oncol off J Am Soc Clin Oncol"},{"key":"5719_CR28","doi-asserted-by":"publisher","first-page":"614521","DOI":"10.3389\/fped.2020.614521","volume":"8","author":"N Vega-Garc\u00eda","year":"2020","unstructured":"Vega-Garc\u00eda N, Perez-Jaume S, Esperanza-Cebollada E et al (2020) Measurable residual disease assessed by Flow-Cytometry is a stable prognostic factor for Pediatric T-Cell Acute Lymphoblastic Leukemia in Consecutive SEHOP protocols whereas the impact of Oncogenetics depends on treatment. Front Pediatr 8:614521. https:\/\/doi.org\/10.3389\/fped.2020.614521","journal-title":"Front Pediatr"},{"key":"5719_CR29","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1182\/blood.2019001557","volume":"135","author":"DT Teachey","year":"2020","unstructured":"Teachey DT, O\u2019Connor D (2020) How I treat newly diagnosed T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma in children. Blood 135:159\u2013166. https:\/\/doi.org\/10.1182\/blood.2019001557","journal-title":"Blood"},{"key":"5719_CR30","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.clml.2014.01.002","volume":"14","author":"Y Zhou","year":"2014","unstructured":"Zhou Y, Slack R, Jorgensen JL et al (2014) The effect of peritransplant minimal residual disease in adults with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation. Clin Lymphoma Myeloma Leuk 14:319\u2013326. https:\/\/doi.org\/10.1016\/j.clml.2014.01.002","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"5719_CR31","doi-asserted-by":"publisher","first-page":"66","DOI":"10.3978\/j.issn.1000-9604.2015.02.04","volume":"27","author":"Y Shi","year":"2015","unstructured":"Shi Y, Zhou S, He X et al (2015) Autologous hematopoietic stem cell transplantation in chemotherapy-sensitive lymphoblastic lymphoma: treatment outcome and prognostic factor analysis. Chin J Cancer Res Chung-Kuo Yen Cheng Yen Chiu 27:66\u201373. https:\/\/doi.org\/10.3978\/j.issn.1000-9604.2015.02.04","journal-title":"Chin J Cancer Res Chung-Kuo Yen Cheng Yen Chiu"},{"key":"5719_CR32","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1007\/s00277-023-05286-3","volume":"102","author":"Y-H Huang","year":"2023","unstructured":"Huang Y-H, Wan C-L, Dai H-P, Xue S-L (2023) Targeted therapy and immunotherapy for T cell acute lymphoblastic leukemia\/lymphoma. Ann Hematol 102:2001\u20132013. https:\/\/doi.org\/10.1007\/s00277-023-05286-3","journal-title":"Ann Hematol"},{"key":"5719_CR33","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1182\/blood.2021014498","volume":"140","author":"P Lu","year":"2022","unstructured":"Lu P, Liu Y, Yang J et al (2022) Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL\/LBL: first-in-human phase 1 clinical trial. Blood 140:321\u2013334. https:\/\/doi.org\/10.1182\/blood.2021014498","journal-title":"Blood"},{"key":"5719_CR34","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1111\/bjh.13771","volume":"174","author":"MR Luskin","year":"2016","unstructured":"Luskin MR, Ganetsky A, Landsburg DJ et al (2016) Nelarabine, cyclosphosphamide and etoposide for adults with relapsed T-cell acute lymphoblastic leukaemia and lymphoma. Br J Haematol 174:332\u2013334. https:\/\/doi.org\/10.1111\/bjh.13771","journal-title":"Br J Haematol"},{"key":"5719_CR35","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1182\/bloodadvances.2022008280","volume":"7","author":"S Shimony","year":"2023","unstructured":"Shimony S, Liu Y, Valtis YK et al (2023) Nelarabine combination therapy for relapsed or refractory T-cell acute lymphoblastic lymphoma\/leukemia. Blood Adv 7:1092\u20131102. https:\/\/doi.org\/10.1182\/bloodadvances.2022008280","journal-title":"Blood Adv"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05719-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05719-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05719-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T02:06:27Z","timestamp":1715565987000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05719-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,6]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["5719"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05719-7","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,6]]},"assertion":[{"value":"8 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the medical Ethics Committee of the Peking University Third Hospital, the Chinese People\u2019s Liberation Army (PLA) General Hospital and the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}